We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 53,336

OIG Finalizes Expanded Exclusion Authorities under ACA
  • Reed Smith LLP
  • USA
  • February 21 2017

On January 12, 2017, the Office of Inspector General (OIG) of the Department


Dechert survey: Developments in securities fraud class actions against U.S. life sciences companies
  • Dechert LLP
  • USA
  • February 21 2017

Life sciences companies continued to be popular targets of securities fraud class action lawsuits filed in 2016, and prudent life sciences companies


Will You, Won't You Join The Biosimilar Patent Dance?
  • Foley & Lardner LLP
  • USA
  • February 21 2017

In the latest dispute surrounding the “patent dance” provisions of the Biologics Price Competition and Innovation Act (BPCIA), Genentech, Inc. has


Life Sciences 2016 Year in Review
  • Bereskin & Parr LLP
  • Canada, USA
  • February 21 2017

This article summarizes Canadian developments in the past year relating to the protection of Life Science innovations. CETA signed - Patent term


Don’t Switch Horses Midstream
  • Marshall Gerstein & Borun LLP
  • USA
  • February 21 2017

In IPR2015-01157, 10X Genomics, Inc. challenged claims 1-31 of USPN 8,889,083 owned by the University of Chicago. PTAB instituted trial on grounds of


Washington Healthcare Update
  • McGuireWoods LLP
  • USA
  • February 20 2017

In a new brief from the House Ways & Means and Energy & Commerce Committees, Republicans outline a plan to pull back Medicaid expansion and convert


Texas 85th Legislature (2017) Legislation Update: Out-of-network billing limitations
  • Husch Blackwell LLP
  • USA
  • February 20 2017

In addition to H.B. 307 (discussed in a prior post), H.B. 1566 and its companion bill, S.B. 507, propose to expand the requirement for mediation of


Non-Physician Learned Intermediaries
  • Reed Smith LLP
  • USA
  • February 20 2017

One of us was asked a question the other day that we couldn’t answer immediately. “Does the learned intermediary rule apply to a physician’s


US bribery and corruption outlook
  • Hogan Lovells
  • USA
  • February 20 2017

Nations across the globe increasingly focus on preventing bribery and corruption and are coordinating their efforts to do so more than ever before


Major Effects of Revised Common Rule on Regulation of Clinical Research in New York
  • Ropes & Gray LLP
  • USA
  • February 17 2017

On January 19, 2017, the U.S. Department of Health and Human Services (HHS), together with 15 other federal Departments and Agencies, issued a final